Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI.

The results reveal that the open concept for all solid tumours characterised for molecular profile and immunotherapy could not only match individualised treatment concepts at a high rate but also underscores the challenges encountered when offering molecularly matched therapies to a patient population with an advanced stage cancer.